In-depth analysis of the human tear proteome

Zhou, Lanlan; Zhao, Shengyuan; Koh, Siew Kwan; Chen, Liyan; Vaz, Candida; Tanavde, Vivek; Li, Xiao Rong; Beuerman, Roger W.

doi:10.1016/j.jprot.2012.04.053

Cited by 279 publications

(269 citation statements)

References 48 publications

(66 reference statements)

Supporting

Mentioning

256

Contrasting

Unclassified

Order By: Relevance

“…For the tear fluid proteome, up to around 1500 proteins have been identified in deep proteomic studies 7. Leonardi et al5 found 78 different proteins in vernal keratoconjunctivitis by iTRAQ quantitative proteomics which is a similar number of proteins found in the present study.…”

Section: Figuresupporting

confidence: 81%

Comparison of tear proteome in allergic rhinoconjunctivitis patients and controls with respect to pollen season

Tomazic

Liesinger

Pucher

et al. 2018

Allergy

View full text Add to dashboard Cite

Section: Figuresupporting

confidence: 81%

Comparison of tear proteome in allergic rhinoconjunctivitis patients and controls with respect to pollen season

Tomazic

Liesinger

Pucher

et al. 2018

Allergy

View full text Add to dashboard Cite

“…CLU mRNA is also abundant in the human lacrimal glands [148,149], meibomian glands [149] and accessory lacrimal glands of Wolfring [150] and mass spectrometric analyses have demonstrated CLU protein in human tears [151][152][153][154][155][156][157][158][159][160][161][162][163][164]. This localization pattern is consistent with the notion of a protective role for CLU at the fluid-tissue interface of the ocular surface epithelia.…”

Section: Ocular Surface Barrier Function In Dry Eye Diseasesupporting

confidence: 61%

Clusterin in the eye: An old dog with new tricks at the ocular surface

Fini

Bauskar

Jeong

et al. 2016

Experimental Eye Research

View full text Add to dashboard Cite

, M. R. (2016). Clusterin in the eye: an old dog with new tricks at the ocular surface. Experimental Eye Research, Clusterin in the eye: an old dog with new tricks at the ocular surface AbstractThe multifunctional protein clusterin (CLU) was first described in 1983 as a secreted glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a variety of cells in vitro. It was also independently discovered in a number of other systems. By the early 1990s, CLU was known under many names and its expression had been demonstrated throughout the body, including in the eye. Its homeostatic activities in proteostasis, cytoprotection, and anti-inflammation have been well documented, however its roles in health and disease are still not well understood. CLU is prominent at fluid-tissue interfaces, and in 1996 it was demonstrated to be the most highly expressed transcript in the human cornea, the protein product being localized to the apical layers of the mucosal epithelia of the cornea and conjunctiva. CLU protein is also present in human tears. Using a preclinical mouse model for desiccating stress that mimics human dry eye disease, the authors recently demonstrated that CLU prevents and ameliorates ocular surface barrier disruption by a remarkable sealing mechanism dependent on attainment of a critical all-or-none concentration in the tears. When the CLU level drops below the critical all-or-none threshold, the barrier becomes vulnerable to desiccating stress. CLU binds selectively to the ocular surface subjected to desiccating stress in vivo, and in vitro to LGALS3 (galectin-3), a key barrier component. Positioned in this way, CLU not only physically seals the ocular surface barrier, but it also protects the barrier cells and prevents further damage to barrier structure. CLU depletion from the ocular surface epithelia is seen in a variety of inflammatory conditions in humans and mice that lead to squamous metaplasia and a keratinized epithelium. This suggests that CLU might have a specific role in maintaining mucosal epithelial differentiation, an idea that can now be tested using the mouse model for desiccating stress. Most excitingly, the new findings suggest that CLU could serve as a novel biotherapeutic for dry eye disease. Competing Interests: US patent 9,241,974 B2 entitled "Clusterin pharmaceuticals and treatment methods using the same" (inventors: MEF and SJ), assigned to the University of Southern California, is connected with this work. MEF holds a management position with Proteris Biotech, Inc., Pasadena, CA, which is developing Protearin for dry eye based on clusterin. MRW declares that he has no competing interests. Page 3 of 65 AbstractThe multifunctional protein clusterin (CLU) was first described in 1983 as a secreted glycoprotein present in ram rete testis fluid that enhanced aggregation ('clustering') of a variety of cells in vitro. It was also independently discovered in a number of other systems. By the early 1990s, CLU was known under many names and its expression had bee...

show abstract

“…Beside these roles, tear provides an effective chemical barrier on the surface of the eye via the secreted antimicrobial and immunomodulatory proteins (AMP), which provide protection against infections [29]. Currently, more than 1500 tear proteins have been identified by proteomics techniques [30][31][32]. Major tear proteins; such as lactotransferrin, lysozyme-C, prolactin-inducible protein, lacritin etc., are involved in the defense against pathogens [31], and their relatively high abundance makes these proteins the major antimicrobial proteins of tear.…”

Section: Tear Fluid As a Source Of Biomarkers For Ocular And Systemicmentioning

confidence: 99%

“…Currently, more than 1500 tear proteins have been identified by proteomics techniques [30][31][32]. Major tear proteins; such as lactotransferrin, lysozyme-C, prolactin-inducible protein, lacritin etc., are involved in the defense against pathogens [31], and their relatively high abundance makes these proteins the major antimicrobial proteins of tear. While many of the tear proteins are produced by the lacrimal glands, some of them originate from epithelial cells; such as dermcidin, defensins, etc., and there are also proteins filtered from the blood such as albumin [33,34].…”

Section: Tear Fluid As a Source Of Biomarkers For Ocular And Systemicmentioning

confidence: 99%

“…The human tear has become one of the most investigated body fluids, being a possible source of biomarkers [30,31]. Tear fluid is one of the non-invasively obtainable body fluids that is relatively easy to collect, and its study may help understand the pathogenesis of ocular and some systemic diseases, in addition to aiding in the prediction of the outcome and scheduling followups for therapeutic sessions.…”

Section: Tear Fluid As a Source Of Biomarkers For Ocular And Systemicmentioning

confidence: 99%

See 1 more Smart Citation

Quantitative body fluid proteomics in medicine — A focus on minimal invasiveness

Csősz

Kalló

Márkus

et al. 2017

Journal of Proteomics

View full text Add to dashboard Cite

In-depth analysis of the human tear proteome

Cited by 279 publications

References 48 publications

Comparison of tear proteome in allergic rhinoconjunctivitis patients and controls with respect to pollen season

Comparison of tear proteome in allergic rhinoconjunctivitis patients and controls with respect to pollen season

Clusterin in the eye: An old dog with new tricks at the ocular surface

Quantitative body fluid proteomics in medicine — A focus on minimal invasiveness

Contact Info

Product

Resources

About